Induction of thioredoxin and mitochondrial survival proteins mediates preconditioning-induced cardioprotection and neuroprotection

Annals of the New York Academy of Sciences

Volumn 1042, Issue , 2005, Pages 403-418

  Chiueh, Chuang C ^a,b   Andoh, Tsugunobu ^c   Chock, P Boon ^d  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^c UNIVERSITY OF TOYAMA   (Japan)

^d NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

Adaptation; ATP sensitive potassium channel K(ATP); Bcl 2; Cyclic GMP; MnSOD; Nitric oxide (NO); Nitric oxide synthase (NOS); Thioredoxin

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 7 NITROINDAZOLE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLIC GMP; CYCLIC GMP DEPENDENT PROTEIN KINASE; FREE RADICAL; GLUCOSE; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 70; MANGANESE SUPEROXIDE DISMUTASE; MITOCHONDRIAL PROTEIN; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; OLIGONUCLEOTIDE; OXYGEN; PROTEIN BCL 2; THIOREDOXIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; CARDIOVASCULAR SYSTEM; CELL PROTECTION; CELL SURVIVAL; CELL VIABILITY; CONFERENCE PAPER; CONTROLLED STUDY; GENETIC TRANSFECTION; HEART INFARCTION PREVENTION; HEART PROTECTION; HORMESIS; HUMAN; HUMAN CELL; LIPID PEROXIDATION; LIVER TRANSPLANTATION; MOUSE; NEUROBLASTOMA CELL; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS;

EID: 22044455180     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1338.034     Document Type: Conference Paper

References (122)

1. VEGH, A., J.G. PAPP, L. SZEKERES, et al. 1992. The local intracoronary administration of mehylene blue prevents the pronounced antiarrhythmic effect of ischaemic preconditioning. Br. J. Pharmacol. 107: 910-911.
2. KATO, H., K. KOGURE, Y. LIU, et al. 1994. Induction of NADPH-diaphorase activity in the hippocampus in a rat model of cerebral ischemia and ischemic tolerance. Brain Res. 652: 71-75.
3. SZILVASSY, Z., P. FERDINANDY, P. BOR, et al. 1994. Loss of preconditioning in rabbits with vascular tolerance to nitroglycerin. Br. J. Pharmacol. 112: 999-1001.
4. CHEN, J., S.H. GRAHAM, R.L. ZHU, et al. 1996. Stress proteins and tolerance to focal cerebral ischemia. J. Cereb. Blood Flow Metab. 16: 566-577.
5. MAULIK, N., R.M. ENGELMAN, J.A. Rousou, et al. 1999. Ischemic preconditioning reduces apoptosis by upregulating anti-death gene Bcl-2. Circulation 100(19 Suppl.): II369-375.
6. Xi, L. 1999. Nitric oxide-dependent mechanism of anti-ischemic myocardial protection induced by monophosphoryl lipid A. Zhongguo Yao Li Xue Bao 20: 865-871.
7. ANDOH, T., S.Y. LEE & C.C. CHIUEH. 2000. Preconditioning regulation of bcl-2 and p66shc by human NOS1 enhances tolerance to oxidative stress. FASEB J. 14: 2144-2146.
8. ILIODROMITIS, E.K., C.C. PAPADOPOULOS, M. MARKIANOS, et al. 1996. Alterations in circulating cyclic guanosine monophosphate (c-GMP) during short and long ischemia in preconditioning. Basic Res. Cardiol. 91: 234-239.
9. DOMOKI, F., J.V. PERCIACCANTE, R. VELTKAMP, et al. 1999. Mitochondrial potassium channel opener diazoxide preserves neuronal-vascular function after cerebral ischemia in newborn pigs. Stroke 30: 2713-2718; discussion 2718-2719.
10. YU, Z.F. & M.P. MATTSON. 1999. Dietary restriction and 2-deoxyglucose administration reduce focal ischemic brain damage and improve behavioral outcome: evidence for a preconditioning mechanism. J. Neurosci. Res. 57: 830-839.
11. YIN, D.P., H.N. SANKARY, A.S. CHONG, et al. 1998. Protective effect of ischemic preconditioning on liver preservation-reperfusion injury in rats. Transplantation 66: 152-157.
12. KLEIN, M., J. GEOGHEGAN, R. WANGEMANN, et al. 1999. Preconditioning of donor livers with prostaglandin 12 before retrieval decreases hepatocellular ischemia-reperfusion injury. Transplantation 67: 1128-1132.
13. FUNG, J.J. 2001. Ischemic preconditioning: application in clinical liver transplantation. Liver Transpl. 7: 300-301.
14. ANDOH, T., P.B. CHOCK & C.C. CHIUEH. 2002. Precoriditioning-mediated neuroprotection: role of nitric oxide, cGMP, and new protein expression. Ann. N.Y. Acad. Sci. 962: 1-7.
15. ANDOH, T., G.C. CHIUEH & P.B. CHOCK. 2003. Cyclic GMP-dependent protein kinase regulates the expression of thioredoxin and thioredoxin peroxidase-1 during hormesis in response to oxidative stress-induced apoptosis. J. Biol. Chem. 278: 885-890.
16. HEURTEAUX, C., I. LAURITZEN, & C. WIDMANN et al. 1995. Essential role of adenosine, adenosine A1 receptors, and ATP-sensitive K+ channels in cerebral ischemic preconditioning. Proc. Natl. Acad. Sci. USA 92: 4666-4670.
17. ELLIOTT, G.T. 1996. Monophosphoryl lipid A: a novel agent for inducing pharmacologic myocardial preconditioning. J. Thromb. Thrombolysis 3: 225-237.
18. RAVATI, A., B. AHLEMEYER, A. BECKER, et al. 2001. Preconditioning-induced neuroprotection is mediated by reactive oxygen species and activation of the transcription factor nuclear factor-kappaB. J. Neurochem. 78: 909-919.
19. ZIMMERMANN, C., I. GINIS, K. FURUYA, et al. 2001. Lipopolysaccharide- induced ischemic tolerance is associated with increased levels of ceramide in brain and in plasma. Brain Res. 895: 59-65.
20. CURRIE, R.W., J.A. ELLISON, R.F. WHITE, et al. 2000. Benign focal ischemic preconditioning induces neuronal Hsp70 and prolonged astrogliosis with expression of Hsp27. Brain Res. 863: 169-181.
21. DIGICAYLIOGLU, M. & S.A. LIPTON. 2001. Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades. Nature 412: 641-647.
22. WICK, A., W. WICK, J. WALTENBERGER, et al. 2002. Neuroprotection by hypoxic preconditioning requires sequential activation of vascular endothelial growth factor receptor and Akt. J. Neurosci. 22: 6401-6407.
23. TRUETTNER, J., R. BUSTO, W. ZHAO, et al. 2002. Effect of ischemic preconditioning on the expression of putative neuroprotective genes in the rat brain. Brain Res. Mol. Brain Res. 103: 106-115.
24. ANDOH, T., RB. CHOCK & C.C. CHIUEH. 2002. The roles of thioredoxin in protection against oxidative stress-induced apoptosis in SH-SY5Y cells. J. Biol. Chem. 277: 9655-9660.
25. DAS, D.K. & N. MAULIK. 2003. Preconditioning potentiates redox signaling and converts death signal into survival signal. Arch. Biochem. Biophys. 420: 305-311.
26. DHODDA, V.K., K.A. SAILOR, K.K. BOWEN, et al. 2004. Putative endogenous mediators of preconditioning-induced ischemic tolerance in rat brain identified by genomic and proteomic analysis. J. Neurochem. 89: 73-89.
27. ONODY, A., A. ZVARA, L. HACKLER, JR., et al. 2003. Effect of classic preconditioning on the gene expression pattern of rat hearts: a DNA microarray study. FEBS Lett. 536: 35-40.
28. HORIMOTO, H., G.R. GAUDETTE, A. E. SALTMAN, et al. 2000. The role of nitric oxide, K(+)(ATP) channels, and cGMP in the preconditioning response of the rabbit. J. Surg. Res. 92: 56-63.
29. CHIUEH, C., S. LEE, T. ANDOH, et al. 2003. Induction of antioxidative and antiapoptotic thioredoxin supports neuroprotective hypothesis of estrogen. Endocrine 21: 27-31.
30. SUZUKI, E., H. KAGEYAMA, T. NAKAKI, et al. 2003. Nitric oxide induced heat shock protein 70 mRNA in rat hypothalamus during acute restraint stress under sucrose diet. Cell. Mol. Neurobiol. 23: 907-915.
31. CHIEN, W.L., K.C. LIANG, C.M. TENG, et al. 2003. Enhancement of long-term potentiation by a potent nitric oxide-guanylyl cyclase activator, 3-(5-hydroxymethyl-2-furyl)-1-benzyl-indazole. Mol. Pharmacol. 63: 1322-1328.
32. KIM, J.S., S. OHSHIMA, P. PEDIADITAKIS, et al. 2004. Nitric oxide protects rat hepatocytes against reperfusion injury mediated by the mitochondrial permeability transition. Hepatology 39: 1533-1543.
33. QIN, Q., X.M. YANG, L. CUI, et al. 2004. Exogenous nitric oxide triggers preconditioning by a cGMP- and mKATP-dependent mechanism. Am. J. Physiol. Heart Circ. Physiol. 287: H712-718.
34. KARCK, M., P. RAHMANIAN & A. HAVERICH. 1996. Ischemic preconditioning enhances donor heart preservation. Transplantation 62: 17-22.
35. KEVELAITIS, E., A. OUBENAISSA, J. PEYNET, et al. 1999. Preconditioning by mitochondrial ATP-sensitive potassium channel openers: an effective approach for improving the preservation of heart transplants. Circulation 100(19 Suppl.): 11345-350.
36. TORRAS, J., I. HERRERO-FRESNEDA, N. LLOBERAS, et al. 2002. Promising effects of ischemic preconditioning in renal transplantation. Kidney Int. 61: 2218-2227.
37. HOLZER, M. & F. STERZ. 2003. Therapeutic hypothermia after cardiopulmonary resuscitation. Expert Rev. Cardiovasc. Ther. 1: 317-325.
38. WANG, H., W. OLIVERO, G. LANZINO, et al. 2004. Rapid and selective cerebral hypothermia achieved using a cooling helmet. J. Neurosurg. 100: 272-277.
39. MAULIK, N., R.M. ENGELMAN, Z. WEI, et al. 1995. Drug-induced heat-shock preconditioning improves postischemic ventricular recovery after cardiopulmonary bypass. Circulation 92: II381-388.
40. RIEFE, M.W. & A.C. LUDOLPH. 1997. Chemical preconditioning: a cytoprotective strategy. Mol. Cell. Biochem. 174: 249-254.
41. NOVALIJA, E., S. FUJITA, J.P. KAMPINE, et al. 1999. Sevoflurane mimics ischemic preconditioning effects on coronary flow and nitric oxide release in isolated hearts. Anesthesiology 91: 701-712.
42. GUO, Z.H. & M.P. MATTSON. 2000. In vivo 2-deoxyglucose administration preserves glucose and glutamate transport and mitochondrial function in cortical synaptic terminals after exposure to amyloid beta-peptide and iron: evidence for a stress response. Exp. Neurol. 166: 173-179.
43. HE, S.Y., H.W. DENG & Y.J. Li. 2001. Monophosphoryl lipid A-induced delayed preconditioning is mediated by calcitonin gene-related peptide. Eur. J. Pharmacol. 420: 143-149.
44. WANG, Y.P., C. SATO, K. MIZOGUCHI, et al. 2002. Lipopolysaccharide triggers late preconditioning against myocardial infarction via inducible nitric oxide synthase. Cardiovasc. Res. 56: 33-42.
45. GARNIER, P., N. BERTRAND, C. DEMOUGEOT, et al. 2002. Chemical preconditioning with 3-nitropropionic acid: lack of induction of neuronal tolerance in gerbil hippocampus subjected to transient forebrain ischemia. Brain Res. Bull. 58: 33-39.
46. RAEBURN, C.D., M.A. ZIMMERMAN, J. ARYA, et al. 2002. Ischemic preconditioning: fact or fantasy? J. Card. Surg. 17: 536-542.
47. KAPINYA, K.J., D. LOWL, C. FUTTERER, et al. 2002. Tolerance against ischemic neuronal injury can be induced by volatile anesthetics and is inducible NO synthase dependent. Stroke 33: 1889-1898.
48. ZAUGG, M., E. LUCCHINETTI, D.R. SPAHN, et al. 2002. Volatile anesthetics mimic cardiac preconditioning by priming the activation of mitochondrial K(ATP) channels via multiple signaling pathways. Anesthesiology 97: 4-14.
49. BOUWMAN, R.A., R.J. MUSTERS, B.J. VAN BEEK-HARMSEN, et al. 2004. Reactive oxygen species precede protein kinase C-delta activation independent of adenosine triphosphate-sensitive mitochondrial channel opening in sevoflurane-induced cardioprotection. Anesthesiology 100: 506-514.
50. DAS, D.K. & N. MAULIK. 2004. Conversion of death signal into survival signal by redox signaling. Biochemistry (Mosc). 69: 10-17.
51. LIU, Y., H. KATO, N. NAKATA, et al. 1993. Correlation between induction of ischemic tolerance and expression of heat shock protein-70 in the rat hippocampus. No. To. Shinkei. 45: 157-162.
52. RAUHALA, P., T. ANDOH, K. YEH, et al. 2002. Contradictory effects of sodium nitroprusside and S-nitroso-N-acetylpenicillamine on oxidative stress in brain dopamine neurons in vivo. Ann. N.Y. Acad. Sci. 962: 60-72.
53. RUSCHER, K., D. FREYER, M. KARSCH, et al. 2002. Erythropoietin is a paracrine mediator of ischemic tolerance in the brain: evidence from an in vitro model. J. Neurosci. 22: 10291-10301.
54. KONOREV, E.A., J. JOSEPH, M.M. TARPEY, et al. 1996. The mechanism of cardioprotection by S-nitrosoglutathione monoethyl ester in rat isolated heart during cardioplegic ischaemic arrest. Br. J. Pharmacol. 119: 511-518.
55. CENTENO, J.M., M. ORTI, J.B. SALOM, et al. 1999. Nitric oxide is involved in anoxic preconditioning neuroprotection in rat hippocampal slices. Brain Res. 836: 62-69.
56. OCKAILI, R., V.R. EMANI, S. OKUBO, et al. 1999. Opening of mitochondrial KATP channel induces early and delayed cardioprotective effect: role of nitric oxide. Am. J. Physiol. 277: H2425-2434.
57. OGAWA, T., A.K. NUSSLER, E. TUZUNER, et al. 2001. Contribution of nitric oxide to the protective effects of ischemic preconditioning in ischemia-reperfused rat kidneys. J. Lab. Clin. Med. 138: 50-58.
58. HAN, J., N. KIM, H. JOO, et al. 2002. ATP-sensitive K(+) channel activation by nitric oxide and protein kinase G in rabbit ventricular myocytes. Am. J. Physiol. Heart Circ. Physiol. 283: H1545-1554.
59. FISCUS, R.R. 2002. Involvement of cyclic GMP and protein kinase G in the regulation of apoptosis and survival in neural cells. Neurosignals 11: 175-190.
60. WIGGINS, A.K., P.J. SHEN & A.L. GUNDLACH. 2003. Neuronal-NOS adaptor protein expression after spreading depression: implications for NO production and ischemic tolerance. J. Neurochem. 87: 1368-1380.
61. CHIUEH, C.C. 1999. Neuroprotective properties of nitric oxide. Ann. N.Y. Acad. Sci. 890:301-311.
62. PAN, S.L., J.H. GUH, Y.L. CHANG, et al. 2004. YC-1 prevents sodium nitroprusside-mediated apoptosis in vascular smooth muscle cells. Cardiovasc. Res. 61: 152-158.
63. RAUHALA, P., A.M. LIN & C.C. CHIUEH. 1998. Neuroprotection by S-nitrosoglutathione of brain dopamine neurons from oxidative stress. FASEB J. 12: 165-173.
64. RAUHALA, P. & C.C. CHIUEH. 2000. Effects of atypical antioxidative agents, S-nitrosoglutathione and manganese, on brain lipid peroxidation induced by iron leaking from tissue disruption. Ann. N.Y. Acad. Sci. 899: 238-254.
65. HANSSON, G.K., H. JORNVALL & S.G. LINDAHL. 1998. The Nobel Prize 1998 in physiology or medicine. Nitrogen oxide as a signal molecule in the cardiovascular system. Ugeskr. Laeger. 160: 7571-7578.
66. MURAD, F. 1999. Cellular signaling with nitric oxide and cyclic GMP. Braz. J. Med. Biol. Res. 32: 1317-1327.
67. CHIUEH, C.C. & P. RAUHALA. 1999. The redox pathway of S-nitrosoglutathione, glutathione and nitric oxide in cell to neuron communications. Free Radic. Res. 31: 641-650.
68. XI, L., D. TEKIN, E. GURSOY, et al. 2002. Evidence that NOS2 acts as a trigger and mediator of late preconditioning induced by acute systemic hypoxia. Am. J. Physiol. Heart Circ. Physiol. 283: H5-12.
69. SALLOUM, F., C. YIN, L. XI, et al. 2003. Sildenafil induces delayed preconditioning through inducible nitric oxide synthase-dependent pathway in mouse heart. Circ. Res. 92: 595-597.
70. JIANG, X., E. SHI, Y. NAKAJIMA, et al. 2004. Inducible nitric oxide synthase mediates delayed cardioprotection induced by morphine in vivo: evidence from pharmacologic inhibition and gene-knockout mice. Anesthesiology 101: 82-88.
71. CUI, J., R.M. ENGELMAN, N. MAULIK, et al. 2004. Role of ceramide in ischemic preconditioning. J. Am. Coll. Surg. 198: 770-777.
72. ZHAO, L., P.A. WEBER, J.R. SMITH, et al. 1997. Role of inducible nitric oxide synthase in pharmacological "preconditioning" with monophosphoryl lipid A. J. Mol. Cell. Cardiol. 29: 1567-1576.
73. LAUDE, K., J. FAVRE, C. THUILLEZ, et al. 2003. NO produced by endothelial NO synthase is a mediator of delayed preconditioning-induced endothelial protection. Am. J. Physiol. Heart Circ. Physiol. 284: H2053-2060.
74. WANG, Y., N. AHMAD, M. KUDO, et al. 2004. Contribution of Akt and endothelial nitric oxide synthase to diazoxide-induced late preconditioning. Am. J. Physiol. Heart Circ. Physiol. 287: H1125-1131.
75. HASHIGUCHI, A., S. YANO, M. MORIOKA, et al. 2004. Up-regulation of endothelial nitric oxide synthase via phosphatidylinositol 3-kinase pathway contributes to ischemic tolerance in the CA1 subfield of gerbil hippocampus. J. Cereb. Blood Flow Metab. 24: 271-279.
76. BERNAUDIN, M., Y. TANG, M. REILLY, et al. 2002. Brain genomic response following hypoxia and re-oxygenation in the neonatal rat. Identification of genes that might contribute to hypoxia-induced ischemic tolerance. J. Biol. Chem. 277: 39728-39738.
77. HAN, J., N. KIM, E. KIM, et al. 2001. Modulation of ATP-sensitive potassium channels by cGMP-dependent protein kinase in rabbit ventricular myocytes. J. Biol. Chem. 276: 22140-22147.
78. GARLID, K.D., P. DOS SANTOS, Z.J. XIE, et al. 2003. Mitochondrial potassium transport: the role of the mitochondrial ATP-sensitive K(+) channel in cardiac function and cardioprotection. Biochim. Biophys. Acta 1606: 1-21.
79. LIU, D., C. LU, R. WAN, et al. 2002. Activation of mitochondrial ATP-dependent potassium channels protects neurons against ischemia-induced death by a mechanism involving suppression of Bax translocation and cytochrome c release. J. Cereb. Blood Flow Metab. 22: 431-443.
80. SORIMACHI, T. & T.S. NOWAK, JR. 2004. Pharmacological manipulations of ATP-dependent potassium channels and adenosine A1 receptors do not impact hippocampal ischemic preconditioning in vivo: evidence in a highly quantitative gerbil model. J. Cereb. Blood Flow Metab. 24: 556-563.
81. SEBILLE, S., P. DE TULLIO, S. BOVERIE, et al. 2004. Recent developments in the chemistry of potassium channel activators: the cromakalim analogs. Curr. Med. Chem. 11: 1213-1222.
82. TAKAGI, Y., A. MITSUI, A. NISHIYAMA, et al. 1999. Overexpression of thioredoxin in transgenic mice attenuates focal ischemic brain damage. Proc. Natl. Acad. Sci. USA 96:4131-4136.
83. KAHLOS, K., Y. SOINI, M. SAILY, et al. 2001. Up-regulation of thioredoxin and thioredoxin reductase in human malignant pleural mesothelioma. Int. J. Cancer 95: 198-204.
84. YOON, B.I., Y. HIRABAYASHI, T. KANEKO, et al. 2001. Transgene expression of thioredoxin (TRX/ADF) protects against 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-induced hematotoxicity. Arch. Environ. Contam. Toxicol. 41: 232-236.
85. TANAKA, T., F. HOSOI, Y. YAMAGUCHI-IWAI, et al. 2002. Thioredoxin-2 (TRX-2) is an essential gene regulating mitochondria-dependent apoptosis. EMBO J. 21: 1695-1703.
86. MITSUI, A., J. HAMURO, H. NAKAMURA, et al. 2002. Overexpression of human thioredoxin in transgenic mice controls oxidative stress and life span. Antioxid. Redox Signal. 4: 693-696.
87. OKUYAMA, H., H. NAKAMURA, Y. SHIMAHARA, et al. 2003. Overexpression of thioredoxin prevents acute hepatitis caused by thioacetamide or lipopolysaccharide in mice. Hepatology 37: 1015-1025.
88. NONN, L., R.R. WILLIAMS, R.P. ERICKSON, et al. 2003. The absence of mitochondrial thioredoxin 2 causes massive apoptosis, exencephaly, and early embryonic lethality in homozygous mice. Mol. Cell. Biol. 23: 916-922.
89. DAMDIMOPOULOS, A.E., A. MIRANDA-VIZUETE, M. PELTO-HUIKKO, et al. 2002. Human mitochondrial thioredoxin. Involvement in mitochondrial membrane potential and cell death. J. Biol. Chem. 277: 33249-33257.
90. CHO, G.G., H.J. KIM, S.W. CHUNG, et al. 2003. Modulation of glutathione and thioredoxin systems by calorie restriction during the aging process. Exp. Gerontol. 38: 539-548.
91. BJORNSTEDT, M., J. XUE, W. HUANG, et al. 1994. The thioredoxin and glutaredoxin systems are efficient electron donors to human plasma glutathione peroxidase. J. Biol. Chem. 269: 29382-29384.
92. AOTA, M., K. MATSUDA, N. ISOWA, et al. 1996. Protection against reperfusion-induced arrhythmias by human thioredoxin. J. Cardiovasc. Pharmacol. 27: 727-732.
93. CASAGRANDE, S., V. BONETTO, M. FRATELLI, et al. 2002. Glutathionylation of human thioredoxin: a possible crosstalk between the glutathione and thioredoxin systems. Proc. Natl. Acad. Sci. USA 99: 9745-9749.
94. UEDA, S., H. MASUTANI, H. NAKAMURA, et al. 2002. Redox control of cell death. Antioxid. Redox Signal. 4: 405-414.
95. YODOI, J., H. NAKAMURA & H. MASUTANI. 2002. Redox regulation of stress signals: possible roles of dendritic stellate TRX producer cells (DST cell types). Biol. Chem. 383: 585-590.
96. BAI, J., H. NAKAMURA, I. HATTORI, et al. 2002. Thioredoxin suppresses 1-methyl-4-phenylpyridinium-induced neurotoxicity in rat PC12 cells. Neurosci. Lett. 321: 81-84.
97. KOBAYASHI-MIURA, M., H. NAKAMURA, J. YODOI, et al. 2002. Thioredoxin, an anti-oxidant protein, protects mouse embryos from oxidative stress-induced developmental anomalies. Free Radic. Res. 36: 949-956.
98. OFFEN, D., P.M. BEART, N.S. CHEUNG, et al. 1998. Transgenic mice expressing human Bcl-2 in their neurons are resistant to 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity. Proc. Natl. Acad. Sci. USA 95: 5789-5794.
99. KLIVENYI, P., D. ST. CLAIR, M. WERMER, et al. 1998. Manganese superoxide dismutase everexpression attenuates MPTP toxicity. Neurobiol. Dis. 5: 253-258.
100. YANG, L., R.T. MATTHEWS, J.B. SCHULZ, et al. 1998. 1-Methyl-4-phenyl-1,2, 3,6-tetrahydropyride neurotoxicity is attenuated in mice overexpressing Bcl-2. J. Neurosci. 18: 8145-8152.
101. FLANAGAN, S.W., R.D. ANDERSON, M.A. ROSS, et al. 2002. Overexpression of manganese superoxide dismutase attenuates neuronal death in human cells expressing mutant (G37R) Cu/Zn-superoxide dismutase. J. Neurochem. 81: 170-177.
102. LEE, S.Y., T. ANDOH, D.L. MURPHY, et al. 2003. 17beta-estradiol activates ICI 182,780-sensitive estrogen receptors and cyclic GMP-dependent thioredoxin expression for neuroprotection. FASEB J. 17: 947-948.
103. MORI, T., H. MURAMATSU, T. MATSUI, et al. 2000. Possible role of the superoxide anion in the development of neuronal tolerance following ischaemic preconditioning in rats. Neuropathol. Appl. Neurobiol. 26: 31-40.
104. CARINI, R. & E. ALBANO. 2003. Recent insights on the mechanisms of liver preconditioning. Gastroenterology 125: 1480-1491.
105. GIDDAY, J.M., A.R. SHAH, R.G. MACEREN, et al. 1999. Nitric oxide mediates cerebral ischemic tolerance in a neonatal rat model of hypoxic preconditioning. J. Cereb. Blood Flow Metab. 19: 331-340.
106. BOLLI, R. 2001. Cardioprotective function of inducible nitric oxide synthase and role of nitric oxide in myocardial ischemia and preconditioning: an overview of a decade of research. J. Mol. Cell. Cardiol. 33: 1897-1918.
107. NAKANO, A., G.S. LIU, G. HEUSCH, et al. 2000. Exogenous nitric oxide can trigger a preconditioned state through a free radical mechanism, but endogenous nitric oxide is not a trigger of classical ischemic preconditioning. J. Mol. Cell. Cardiol. 32: 1159-1167.
108. SAITOH, M., H. NISHITOH, M. FUJII, et al. 1998. Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J. 17: 2596-2606.
109. KOJIMA, S., O. MATSUKI, T. NOMURA, et al. 1999. Elevation of antioxidant potency in the brain of mice by low-dose gamma-ray irradiation and its effect on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced brain damage. Free Radic. Biol. Med. 26: 388-395.
110. RYBNIKOVA, E., A.E. DAMDIMOPOULOS, J.A. GUSTAFSSON, et al. 2000. Expression of novel antioxidant thioredoxin-2 in the rat brain. Eur. J. Neurosci. 12: 1669-1678.
111. ZHANG, R., R. AL-LAMKI, L. BAI, et al. 2004. Thioredoxin-2 inhibits mitochondria-located ASK1-mediated apoptosis in a JNK-independent manner. Circ. Res. 94: 1483-1491.
112. HOLMUHAMEDOV, E.L., A. JAHANGIR, A. OBERLIN, et al. 2004. Potassium channel openers are uncoupling protonophores: implication in cardioprotection. FEBS Lett. 568: 167-170.
113. HIROTA, K., H. NAKAMURA, H. MASUTANI, et al. 2002. Thioredoxin superfamily and thioredoxin-inducing agents. Ann. N.Y. Acad. Sci. 957: 189-199.
114. MOUSSAOUI, S., M.C. OBINU, N. DANIEL, et al. 2000. The antioxidant ebselen prevents neurotoxicity and clinical symptoms in a primate model of Parkinson's disease. Exp. Neurol. 166: 235-245.
115. ZHAO, R. & A. HOLMGREN. 2004. Ebselen is a dehydroascorbate reductase mimic, facilitating the recycling of ascorbate via mammalian thioredoxin systems. Antioxid. Redox Signal. 6: 99-104.
116. TENG, C.M., C.C. Wu, F.N. Ko, et al. 1997. YC-1, a nitric oxide-independent activator of soluble guanylate cyclase, inhibits platelet-rich thrombosis in mice. Eur. J. Pharmacol. 320: 161-166.
117. HWANG, T.L., C.C. Wu & C.M. TENG. 1999. YC-1 potentiates nitric oxide-induced relaxation in guinea-pig trachea. Br. J. Pharmacol. 128: 577-584.
118. MARTIN, E., Y.C. LEE & F. MURAD. 2001. YC-1 activation of human soluble guanylyl cyclase has both heme-dependent and heme-independent components. Proc. Natl. Acad. Sci. USA 98: 12938-12942.
119. MURAD, F. 2003. The excitement and rewards of research with our discovery of some of the biological effects of nitric oxide. Circ. Res. 92: 339-341.
120. GOMMA, A.H., H.J. PURCELL & K.M. FOX. 2001. Potassium channel openers in myocardial ischaemia: therapeutic potential of nicorandil. Drugs 61: 1705-1710.
121. DANIEL, H., N. HEMART, D. JAILLARD, et al. 1993. Long-term depression requires nitric oxide and guanosine 3′:5′ cyclic monophosphate production in rat cerebellar Purkinje cells. Eur. J. Neurosci. 5: 1079-1082.
122. SHIBUKI, K. & D. OKADA. 1991. Endogenous nitric oxide release required for long-term synaptic depression in the cerebellum. Nature 349: 326-328.